Dr Sharman says in his latest blog "The abstract I have been most eager to review in this years ASH meeting details the results of the German CLL10 study in which FCR (fludarabine, cyclophosphamide, rituximab) is compared to BR (bendamustine, rituximab) in the front line management of patients with symptomatic CLL"
Those of us nearing treatment are also eager to learn what this study has discovered!
Read more at:
Hopefully BR or even better BR+? will soon be available for those of us where FCR is perhaps not the better choice due to our age or other factors such as renal function and medical comorbidities.